Drug Profile
Enoxaparin sodium biosimilar - Biocad
Alternative Names: BCD 080; Enoxaparin biosimilar - BiocadLatest Information Update: 15 Feb 2022
Price :
$50
*
At a glance
- Originator Biocad
- Class Anti-ischaemics; Antithrombotics; Ischaemic heart disorder therapies; Low molecular weight heparins
- Mechanism of Action Factor Xa inhibitors; Thrombin inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Deep vein thrombosis; Venous thromboembolism
Most Recent Events
- 15 Feb 2022 Discontinued - Phase-III for Deep vein thrombosis (In the elderly, Prevention, In adults) in Russia (SC) (Biocad pipeline, February 2022)
- 15 Feb 2022 Discontinued - Phase-III for Venous thromboembolism (In the elderly, Prevention, In adults) in Russia (SC) (Biocad pipeline, February 2022)
- 01 Jan 2015 Phase-III clinical trials in Deep vein thrombosis (In adults, In the elderly, Prevention) in Russia (SC) (NCT02368314)